Stockreport

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart [Yahoo! Finance]

Cardiol Therapeutics Inc. - Class A Common Shares  (CRDL) 
PDF life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's Pres [Read more]